Cramer's 'Mad Money' Recap: Good Cheap Stocks

The only thing not to like about Intuitive is its $285 price tag, but that's just an "illusion," Cramer said. This stock has "king growth" and should go higher. He set his new price target for Intuitive at $358.

Sticking with Schering-Plough

Cramer told viewers he's been reading through Microtrends: The Small Forces Behind Tomorrow's Big Changes by Mark Penn, and it has helped him think of Schering-Plough (SGP Quote) as a stock worth considering.

Skin cancer, he said, is the most common type of cancer and its mortality rate is up 50% since 1970s, but most people are not aware of this.

Cramer said he's liked Schering as a turnaround story for a while, but today the stock got pummeled. Its cholesterol division was flat and the Street was looking for more growth. However, Cramer said he's leaning toward believing it's an entry point to get into the stock because it has many phase III drugs in the works, including one for prostate cancer and one for female infertility. "These could be huge," he said.

That said, Cramer welcomed CEO Fred Hassan to the show and asked him what went wrong with the stock.

"Today is no different than yesterday, and this is what I call the no-guidance effect," Hassan said. "Having a no-guidance policy, there are some quarters where there is an undershoot and some quarters when there is an overshoot."